CPS Technologies Q2: The Capital Raise Story Disguised as a Demand Story

Consensus View vs. Structural Reality

CPS Technologies reported Q2 fiscal 2026 revenue of $8.3 million on August 4th, up from $8.1 million a year earlier and well above the $7.0 million Q1 result. CEO Brian Mackey described "strong demand across our various product lines" and called the quarter a recovery story, pointing to gross margins that rebounded 620 basis points from Q1's 8.6% trough to 14.8%. The stock rose 5.3% on the news.

The framing is wrong. This is not a demand story. It is a capital consumption story that has been recast as an execution narrative. What the numbers actually show is a company that has raised approximately $20 million in equity over the past 10 months - two separate offerings totaling a $9.6 million registered direct in May and a $9.5 million net proceeds from a public offering in October 2025 - to fund a manufacturing facility relocation that has been promised repeatedly but has not yet materialized. On a $33 million annualized revenue run-rate, the equity raises equal more than six months of total revenue. At an approximately $87 million market cap with 19.4 million shares outstanding, the capital raises represent a meaningful fraction of the company's own equity value.

The Margin Math

The margin recovery from Q1 to Q2 is real but misleadingly presented. Q1's 8.6% gross margin was not a structural problem - it was the accounting impact of lower revenue on fixed costs combined with the deliberate inventory build ahead of the planned facility move. Management itself acknowledged as much, stating the margin compression was due to "the impact of lower revenue on fixed costs as well as cost accounting related to adding over $1.5 million to inventory." Q2's 14.8% margin is still below last year's 16.5% on essentially the same revenue level. The recovery is a function of revenue normalizing from the Q1 trough, not of structural improvement.

More concerning is the operating picture. CPS posted an operating loss of $0.2 million in Q2 compared to an operating profit of $0.1 million a year earlier, with SG&A expenses rising approximately $0.3 million year-over-year on revenue that grew only 2.5%. That is a leverage ratio that works against the company: costs are growing faster than top-line growth, and the gap widens as you move from gross margin down to the operating line.

Net income for the quarter was $40,000 - effectively zero. On a per-share basis, that is $0.00, compared to $0.01 a year ago. The company is not generating meaningful earnings on $8.3 million of quarterly revenue.

The Facility Move: The Constraint That Has Not Moved

The planned relocation to a larger manufacturing facility is the central structural element of every CPS earnings release since mid-2025. It has appeared in the Q3 2025 release, the Q1 2026 release, and now the Q2 2026 release. In each case, management advances the same narrative: the move will enable efficiency, support growth, and improve margins. In each case, the timeline is "coming quarters."

That pattern matters because a manufacturing company that cannot execute a facility move is a company whose capex trajectory does not match its revenue trajectory. The $15.5 million semiconductor contract announced in October 2025 - representing a 16.5% year-over-year increase from one customer - is precisely the type of order that requires production capacity. If the facility is not ready, the company is either (a) absorbing the incremental volume at current constrained margins, or (b) risking execution on a contract that justifies the capital raise it used to fund. Either way, the facility move is the constraint.

What is not clear from the earnings release is the timeline. The company is "finalizing negotiations for the best available site." That is not a timeline. That is pre-construction. And the cost of the delay is measured in the gap between 14.8% gross margins and the structural margin the company claims a larger facility would deliver.

The Capital Structure Problem

The broader picture is harder to miss when you stack the numbers. CPS has raised $9.5 million in net proceeds from a public offering in October 2025 and $9.6 million from a registered direct in May 2026. The stock now trades at approximately $4.48. With $33 million in annualized revenue and essentially zero operating profit, the company's business model requires continuous capital infusion to bridge the gap between revenue generation and the capex needed to scale. That is not a sustainable capital structure for a manufacturing company.

The defense and space programs - the Army's tungsten warhead contract, the Navy's Amphibious Combat Vehicle SBIR extension - provide some revenue diversification, but these are small-dollar funded research programs measured in hundreds of thousands of dollars, not the multi-million-dollar contracts that would change the capital structure math.

Investor Takeaway

The key issue for CPS Technologies is not whether demand exists - the $15.5 million semiconductor contract and the $4 million hermetic packaging order booked after Q1 confirm that orders are there. The more important question is whether the company can execute the facility move fast enough to convert incremental volume into meaningful margin expansion before the current equity position is consumed by operating losses and further capital requirements.

The company now needs to provide a specific timeline for the facility relocation - not "coming quarters," but a date. Until that happens, the stock remains a bet on capex execution, not a business generating returns on capital. The structural thesis is that CPS is an advanced materials job shop with a capacity problem dressed up as a growth story. The evidence to confirm or break that thesis will come from the next earnings release: if Q3 revenue exceeds $8.5 million without the new facility, the demand case holds. If margins stay below 15%, the structural constraint is still in place, and the capital consumption problem has not been solved.